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Colistin resistance in Klebsiella pneumoniae is predominantly caused by mutations 20 
that increase expression of the arn (also known as pbg or pmrF) operon. Expression is 21 
activated by the PhoPQ and PmrAB two-component systems. Constitutive PhoPQ 22 
activation occurs directly by mutation or following loss of MgrB. PhoPQ may also 23 
cross-activate PmrAB via the linker protein PmrD. Using proteomics, we show that 24 
MgrB loss causes a wider proteomic effect than direct PhoPQ activation, suggesting 25 
additional targets for MgrB. Different mgrB mutations cause different amounts of Arn 26 
protein production, which correlated with colistin MIC. Disruption of phoP in an mgrB 27 
mutant had a reciprocal effect to direct activation of PhoQ in a wild-type background, 28 
but the regulated proteins showed almost total overlap. Disruption of pmrD or pmrA 29 
slightly reduced Arn protein production in an mgrB mutant, but production was still 30 
high enough to confer colistin resistance; disruption of phoP conferred wild-type Arn 31 
production and colistin MIC. Activation of PhoPQ directly, or through mgrB mutation 32 
did not significantly activate PmrAB or PmrC production but direct activation of PmrAB 33 
by mutation did, and also activated Arn production and conferred colistin resistance. 34 
There was little overlap between the PmrAB and PhoPQ regulons. We conclude that 35 
under the conditions used for colistin susceptibility testing, PhoPQ-PmrD-PmrAB 36 
cross-regulation is not significant and that independent activation of PhoPQ or PmrAB 37 
is the main reason that Arn protein production increases above the threshold required 38 





Colistin is increasingly used to treat infections caused by extensively drug resistant Gram-41 
negative bacteria (1). Colistin resistance in carbapenem-resistant Klebsiella pneumoniae, 42 
which was first reported in 2010 (2-4) is, therefore, a critically important problem. It can be 43 
caused by mobile mcr genes but by far the most common causes in K. pneumoniae and some 44 
other Enterobacteriaceae species are chromosomal mutations (5,6). For example, loss-of-45 
function mutations in mgrB regularly emerge following colistin therapy in the clinic, and when 46 
selecting resistant mutants in the laboratory (7-10). Loss of MgrB causes activation of arn 47 
operon expression (7). This operon, also referred to as the pbg or pmrF operon (5) encodes 48 
a series of enzymes forming a pathway that modifies lipid A in lipopolysaccharide by adding 49 
4‐amino‐4‐deoxy‐L‐arabinose. This modification has been seen in colistin resistant K. 50 
pneumoniae mutants in many studies (e.g. 11-13). Its effect is to reduce cell surface negative 51 
charge, reducing affinity for positively charged colistin, raising its MIC (5). 52 
Activation of arn operon transcription in K. pneumoniae involves two upstream promoters, 53 
each targeted by a two-component system response regulator. PhoP targets promoter 1 in 54 
response to low magnesium concentrations and PmrA targets promoter 2 in response to high 55 
iron concentrations and low pH (14). The dramatic impact that cations and pH have on arn 56 
promoter activity explains the wide range of medium-dependent colistin MICs observed in the 57 
laboratory (15,16). According to a joint CLSI and EUCAST report, colistin susceptibility testing 58 
needs to be tightly standardised, therefore, and the gold standard is broth microdilution using 59 
colistin sulphate, cation adjusted Muller Hinton broth and with no additives (17) 60 
Additional complexity arises in control of arn operon transcription in K. pneumoniae because 61 
the response regulator PhoP can also activate transcription of pmrD and PmrD binds PmrA 62 
and enhances its activation (14,18). Hence, when low magnesium and high iron occur at the 63 
same time, the PmrA-targeted arn operon promoter 2 is more strongly activated than it is in 64 




The cognate sensor kinases activating PhoP and PmrA are PhoQ and PmrB, respectively 66 
(14). It is generally accepted that loss-of-function mutations in mgrB activate arn operon 67 
transcription in K. pneumoniae because MgrB is a direct negative regulator of PhoQ sensor 68 
kinase activity, as in some other Enterobacteriaceae species (5). In fact, this is experimentally 69 
confirmed only in Salmonella spp. (19) but loss of MgrB does constitutively activate PhoPQ in 70 
K. pneumoniae, leading to constitutively enhanced transcription from arn operon promoter 1 71 
(14). Specific mutations in PhoPQ also activate arn operon transcription and confer colistin 72 
resistance or heteroresistance in K. pneumoniae, e.g. PhoQ substitutions Asp434Asn (20) or 73 
Ala21Ser (21) or PhoP substitution Asp191Tyr (22).  74 
Mutations in PmrAB, constitutively activating arn operon transcription from promoter 2 have 75 
also been found to cause colistin resistance in K. pneumoniae. For example, Leu82Arg (23) 76 
or Thr157Pro (24) in PmrB, but activation of PmrAB also increases expression of pmrC. This 77 
encodes an enzyme that modifies lipopolysaccharide by decorating it with 78 
phosphoethanolamine, which contributes to colistin resistance in Salmonella spp. because it 79 
is another way to reduce negative charge on the cell surface (25).  80 
A third two-component regulatory system known to be involved in colistin resistance in K. 81 
pneumoniae is CrrAB. Activatory mutations in the sensor kinase CrrB have been identified in 82 
colistin resistant clinical isolates (20,26,27). Based on transcriptomic analysis these mutants 83 
have increased arn operon and pmrC transcription (20) and in this they closely resemble 84 
PmrAB activatory mutants and indeed pmrAB is essential for the activation of arn operon and 85 
pmrC transcription in CrrAB activatory mutants, suggesting direct linkage between these two-86 
component systems (26). One additional effect of CrrAB activation is upregulation of crrC 87 
transcription (20) and crrC is also essential for activation of arn operon and pmrC transcription 88 
in a CrrAB activatory mutant (26). This suggests that CrrC forms the link between activated 89 
CrrAB and activation of PmrAB, leading to colistin resistance, but the mechanism by which 90 




The complexity associated with acquisition of colistin resistance in K. pneumoniae, means that 92 
clinical cases involve a wide range of mutations. In a recent large clinical survey, mgrB loss-93 
of-function was the most common mechanism, but in many cases, additional mutations in two-94 
component system genes was seen, and in cases where multiple mutations were seen, a 95 
sequential increase in colistin MIC was observed (28) 96 
The aim of the work reported here was to use LC-MS/MS shotgun proteomics and targeted 97 
mutagenesis to investigate the importance of the MgrB-PhoPQ-PmrD-PmrAB signal 98 
transduction pathway to modulate Arn protein and PmrC production, and assess the protein 99 
abundance thresholds required for colistin resistance in K. pneumoniae stimulated by 100 
mutations affecting PhoPQ and/or PmrAB activity. 101 
 102 
Results and Discussion 103 
The direct role of PhoPQ and the indirect role of signal transduction from PhoPQ through 104 
PmrD to PmrAB in Arn protein production and colistin resistance caused by mgrB mutation. 105 
A collection of six K. pneumoniae spontaneous single-step mutants were selected in the 106 
laboratory using Muller-Hinton agar containing 32 µg.mL-1 of colistin, and in each case, PCR 107 
and whole genome sequencing confirmed only mutation in mgrB or upstream. Three different 108 
mutations were seen, causing the following changes: Gln29STOP in MgrB (found in four 109 
colistin resistant mutants here, represented by mutant P21); an A to G transition at -31 relative 110 
to the mgrB start codon, weakening a putative second -10 promoter sequence (Figure S1) 111 
(represented by mutant P22); a deletion comprising the region between -19 relative to the start 112 
codon, to remove the first 41 amino acids of MgrB (represented by mutant P23).  113 
Colistin MICs against these three representative mutants were determined and, in all cases, 114 
colistin resistance was confirmed (Table 1). Envelope proteomics identified 45 proteins 115 
significantly differentially regulated in all three mgrB mutants relative to the parent strain, Ecl8 116 




known to be responsible for modification of lipopolysaccharide by the addition of 4-amino-4-118 
deoxy-L-arabinose (5). Figure 1 shows that Arn protein production is highest in the mutant 119 
P23, where MgrB is entirely lost. The mgrB nonsense mutant truncated at 29 amino acids, 120 
P22 and the mgrB promoter mutant P21 both have significantly lower Arn protein production 121 
than in P23, implying some residual repressive activity of MgrB in both cases. Overall, P22 122 
had the lowest Arn protein production of the three (Figure 1). Nonetheless all three mutants 123 
are colistin resistant though, as expected based on Arn protein production levels, the highest 124 
MIC is against P23 and the lowest against P22 (Table 1). This leads to the conclusion that 125 
once Arn protein production increases above a certain threshold, colistin resistance is 126 
conferred, but that as protein production increases further (P23>P21>P22) MIC also 127 
increases. 128 
It has been proposed that, in K. pneumoniae, arn operon gene expression is increased upon 129 
mgrB mutation through activation of the two-component system PhoPQ, and that in addition, 130 
there is a secondary increase through activation of the PmrAB two-component system, with 131 
PmrD being necessary for transducing PhoPQ activation into PmrAB activation (5). Using 132 
mgrB mutant P23 as a starting point, we disrupted phoP, pmrD and pmrA, to test the effects 133 
of these mutations on Arn protein production and colistin MIC. 134 
Observed Arn protein abundance changes in these regulatory mutants demonstrated the 135 
primacy of PhoPQ activation in colistin resistance driven by mgrB loss. Arn protein abundance 136 
returned to wild-type (Figure 2) and colistin MIC fell below the resistance breakpoint (Table 137 
1) upon disruption of phoP in the mgrB mutant P23. In contrast, our proteomics analysis 138 
(Figure 2) showed that PmrD and PmrAB play only a minor role in increased Arn protein 139 
production seen in an mgrB mutant. Only ArnC significantly reduced in abundance following 140 
disruption of pmrA. There was a larger effect following disruption of pmrD (4/5 Arn proteins 141 
significantly reduced in abundance) but in neither mutant did any of the Arn proteins fall in 142 
abundance significantly below levels seen in the mgrB mutants P21 and P22 (Figure 1) and 143 




remained colistin resistant (Table 1). These data add support for our conclusion that there is 145 
a threshold of Arn protein abundance required for colistin resistance. It seems clear that 146 
PhoPQ activation alone can support an abundance above this threshold even without any 147 
additional effects caused by PmrAB activation. 148 
 149 
PhoPQ regulated proteins identified following mgrB mutation and PhoQ activation. 150 
Of 45 proteins (i.e. including the Arn proteins) differentially regulated in all three mgrB mutants 151 
(Table S1) 18 of those upregulated in the mgrB mutant P23 returned to wild-type levels upon 152 
disruption of phoP (Table 2). These included the five Arn proteins, the response regulator 153 
PhoP itself, LpxO, two Mg2+ transporters including MgtA, SlyB and MacA. Transcripts 154 
representing all these proteins have been seen to be upregulated in mgrB loss-of-function and 155 
in PhoQ activatory (PhoQ*) colistin resistant clinical isolates relative to colistin susceptible 156 
control isolates through transcriptomics (20). Our proteomics analysis reinforces the definition 157 
of a core PhoPQ regulon, but a secondary observation is that the majority (27/45) of the protein 158 
abundance changes seen in the mgrB mutant P23 (Table S1) do not occur via activation of 159 
PhoPQ; they were not reversed following disruption of phoP (Table 2). The implication of this 160 
finding, made here by comparing otherwise isogenic pairs of strains, is that MgrB interacts 161 
with regulatory networks other than PhoPQ in K. pneumoniae, though these additional effects 162 
are not important for colistin resistance, which was completely reversed following disruption 163 
of phoP (Table 1). 164 
In order to further investigate the role of direct PhoPQ activation in colistin resistance, we 165 
turned to a colistin resistant, PhoQ* (activatory) mutant that we selected from K. pneumoniae 166 
clinical isolate KP47 (Table 1). Whole genome sequencing identified the mutation causes a 167 
Tyr89Asn change in PhoQ. Proteomics comparing KP47 with the PhoQ* mutant derivative 168 
revealed that levels of Arn protein production in the PhoQ* mutant were not significantly 169 




starting with a different parent strain, significant upregulation of 15/18 proteins seen to become 171 
downregulated when phoP was disrupted in the Ecl8-derived mgrB mutant P23 were also 172 
upregulated in the PhoQ* mutant relative to its parent, KP47. This further focussed down onto 173 
the core K. pneumoniae PhoPQ regulon, which is shown in Table 2.  174 
 175 
Proteins upregulated following activation of PmrAB. 176 
It has been reported that PmrAB activation directly by mutation can confer colistin resistance 177 
(23,24) and we were able to select a colistin resistant mutant of clinical isolate KP47 with an 178 
activatory mutation in PmrB (Table 1). The mutation identified using whole genome 179 
sequencing was Thr157Pro. Arn protein abundance in this PmrB* mutant was significantly 180 
elevated relative to KP47 in all cases except for ArnB. For all except ArnA and ArnB the extent 181 
of abundance increase was like that seen in the PhoQ* derivative of KP47, and the mgrB 182 
mutant P23 (Figure 3). In total, however, only 7/45 proteins significantly up- or down-regulated 183 
in the mgrB mutant P23 were significantly up- or down-regulated in the PmrB* mutant. As well 184 
as the Arn proteins (except ArnB), these were SlyB, LpxO and one Mg2+ transporter, which 185 
are all part of the core PhoPQ regulon (Table S1). Transcripts representing all seven of these 186 
PrmAB/PhoPQ dual regulated proteins, plus ArnB have also been seen to be upregulated in 187 
clinical isolates with activatory mutations in CrrB (20) which indirectly activates PmrAB (26,27).  188 
The fact that ArnB abundance did not increase significantly above the level seen in wild-type 189 
KP47 was surprising since the PmrB* mutant is colistin resistant (Table 1). This suggested 190 
that either significant upregulation of ArnB is not essential for colistin resistance or there is 191 
another mechanism involved in colistin resistance in the PmrB* mutant. To identify a possible 192 
additional mechanism, we searched the 65 proteins differentially regulated in the PmrB* 193 
mutant relative to KP47. Three of those most strongly over-produced were PmrA, PmrB and 194 
PmrC (Figure 4). Transcription of pmrC (also known as eptA) is known to be positively 195 




phosphoethanolamine transferase, responsible for modifying lipopolysaccharide by 197 
decorating it with phosphoethanolamine, and this increases the MIC of colistin (25).  198 
 199 
Little evidence for PhoPQ-PmrD-PmrAB mediated signal transduction for in vitro colistin 200 
resistance in K. pneumoniae. 201 
As shown above, disruption of pmrD or pmrA in an mgrB loss-of-function mutant did not reduce 202 
Arn protein production below a threshold required for colistin resistance (Figure 2, Table 1). 203 
It was also interesting to find that PmrA, B or C were not produced above our limit of detection 204 
(around 100 times less than the level seen in the PmrB* mutant) in any mgrB loss-of-function 205 
mutant or in the PhoQ* mutant (Figure 4). These two findings lead us to conclude that cross 206 
activation of PmrAB (the direct regulator of pmrC) following activation of PhoPQ is very limited 207 
under the growth conditions used for our analysis. 208 
Our observation that the phosphoethanolamine transferase PmrC is unique to the PmrAB-209 
mediated branch of the colistin resistance-mediating regulatory system may well explain why, 210 
of multiple studies monitoring the impact of mgrB loss-of-function on lipopolysaccharide 211 
modification in K. pneumoniae (11-13, 29) only one has reported elevated levels of 212 
phosphoethanolamine modification (29). Indeed, even in this case, contrary to expectations, 213 
the observed modification, and the observed upregulation of pmrC expression were both 214 
apparently dependent on PhoPQ but not PmrAB, suggesting it was not caused by PhoPQ-215 
PmrD-PmrAB cross-regulation at all (29). Furthermore, the authors showed that pmrC 216 
disruption in an mgrB loss-of-function mutant background only had a small impact on survival 217 
in the presence of colistin (29). This implies that even when rarely seen, phosphoethanolamine 218 
modification by PmrC has only a minor role in colistin resistance in K. pneumoniae. Indeed, 219 
an absence of phosphoethanolamine modification has been advocated as a way to identify 220 




modification) whether due to mgrB loss-of-function mutation, PhoPQ activation or PmrAB 222 
activation in K. pneumoniae (30).  223 
The reason why other earlier seminal reports have placed far higher importance on the cross-224 
activation of PmrAB by PhoPQ via PmrD in K. pneumoniae (14,18) could be that they used 225 
growth media that caused greater basal activation of PmrAB. It is important to remember that 226 
the PmrD linker protein has only experimentally been shown to increase the activation of 227 
PmrAB once PmrAB has been activated by an external signal, not to activate PmrAB from the 228 
basal state (14,18). Since PmrAB activation is affected by iron concentration and pH, it may 229 
be that the medium used for colistin susceptibility testing – and used by us here – does not 230 
activate PmrAB in the first place, so there is nothing that PmrD can do to enhance activation, 231 
effectively silencing the cross-regulatory pathway. Indeed, it is worth noting that in some 232 
Enterobacteriaceae species, e.g. Enterobacter cloacae, there is no pmrD gene and that 233 
PhoPQ and PmrAB work independently to regulate arn operon transcription (31). 234 
Another explanation for differences between the conclusions of ours and previous work is that 235 
previous work relied on measurements of transcript levels. In some cases, small changes in 236 
protein abundance are associated with phenotypically relevant changes in antimicrobial 237 
susceptibility, as we have shown previously in K. pneumoniae, for example upon loss-of-238 
function mutations in ramR, which, despite having <5 fold effects on OmpK35 porin and 239 
AcrAB-TolC efflux pump production, has large effects on susceptibility to a range of 240 
antimicrobial agents from different classes (32). But in some cases, large changes in gene 241 
expression are required to have a phenotypic effect when a gene is not highly expressed in 242 
the wild-type, for example in the case of OqxAB efflux pump production as controlled by OqxR 243 
in K. pneumoniae, which needs to increase >10,000 fold to have a phenotypic effect on 244 
resistance (33). One major advantage of proteomics is that comparisons of protein abundance 245 
can be drawn between different gene products, which is not always the case when transcript 246 
levels are measured, since the kinetics of DNA hybridisation can have major influences on 247 




be constitutive in K. pneumoniae, and not part of the PhoPQ or PmrAB regulons (Figure 4), 249 
where it is controlled by both regulators in Salmonella spp. (5). In the context of PmrB 250 
activation in K. pneumoniae, constitutive expression of pmrE has also been shown by qRT-251 
PCR (26) and in the context of CrrB activation – leading to PmrAB activation – this has been 252 
shown through transcriptomics (20). The added value of proteomics is that we can conclude 253 
that PmrE, which is an enzyme responsible for driving the committed step for the biosynthesis 254 
of 4‐amino‐4‐deoxy‐L‐arabinose required for colistin resistance (5), is present at levels in wild-255 
type cells similar to the levels of Arn protein produced in colistin resistant mutants rather than 256 
its production being constitutive but at low levels (Figures 3, 4). 257 
 258 
Conclusions 259 
We conclude that colistin resistance caused by PhoPQ activation in conditions defined for 260 
colistin susceptibility testing – i.e. in most clinical cases (28) – is due almost exclusively to 261 
direct Arn protein upregulation. Whilst PmrAB activation can also cause Arn protein 262 
upregulation and colistin resistance, there is no evidence for significant activation of PmrAB 263 
via PmrD as an additional mechanism for upregulating Arn proteins following PhoPQ activation 264 
under these growth conditions. We also conclude that the level of Arn protein upregulation 265 
dictates colistin MIC. It is interesting to note, therefore that clinical isolates with multiple 266 
mutations activating PhoPQ can be found, where there is an additive effect on colistin MIC 267 
(28). The implication is that real-world colistin usage in the clinic in some cases selects for 268 
mutations or combinations of mutations that confer colistin MICs above the currently defined 269 








Materials, bacterial isolates, selection and generation of mutants 275 
Chemicals were from Sigma and growth media from Oxoid, unless otherwise stated. Strains 276 
used were K. pneumoniae Ecl8 (34), plus the clinical isolate KP47 (35). To select colistin 277 
resistant mutants, one hundred microlitre aliquots of overnight cultures of the parent strain 278 
grown in Cation Adjusted Muller-Hinton Broth (CAMHB) were spread onto Mueller-Hinton Agar 279 
containing 32 µg.mL-1 colistin, which were then incubated for 24 h. Insertional inactivation of 280 
phoP, pmrD, or pmrA was performed using the pKNOCK suicide plasmid (36). The phoP, 281 
pmrD and pmrA DNA fragments were amplified with Phusion High-Fidelity DNA Polymerase 282 
(NEB, UK) from K. pneumoniae Ecl8 genomic DNA by using primers listed in Table S2. Each 283 
PCR product was ligated into the pKNOCK-GM at the SmaI site. The recombinant plasmid 284 
was then transferred into K. pneumoniae cells by conjugation. Mutants were selected for 285 
gentamicin non-susceptibility (5 µg.mL-1) and the mutation was confirmed by PCR using 286 
primers listed in Table S2. 287 
 288 
Determining MICs of colistin 289 
MICs were determined using CLSI broth microtitre assays (37) and interpreted using published 290 
breakpoints (38). Briefly, a PBS bacterial suspension was prepared to obtain a stock of 291 
OD600=0.01. The final volume in each well of a 96-well cell culture plate (Corning Costar) was 292 
200 µL and included 20 µL of the bacterial suspension. Bacterial growth was determined after 293 
20 h of incubation by measuring OD600 values using a POLARstar Omega spectrophotometer 294 








500 µL of an overnight CAMHB culture were transferred to 50 mL CAMHB and cells were 300 
grown at 37˚C to 0.6 OD600. Cells were pelleted by centrifugation (10 min, 4,000 × g, 4°C) and 301 
resuspended in 30 mL of 30 mM Tris-HCl, pH 8 and broken by sonication using a cycle of 1 s 302 
on, 0.5 s off for 3 min at amplitude of 63% using a Sonics Vibracell VC-505TM (Sonics and 303 
Materials Inc., Newton, Connecticut, USA). The sonicated samples were centrifuged at 8,000 304 
rpm (Sorval RC5B PLUS using an SS-34 rotor) for 15 min at 4°C to pellet intact cells and large 305 
cell debris. For envelope preparations, the supernatant was subjected to centrifugation at 306 
20,000 rpm for 60 min at 4°C using the above rotor to pellet total envelopes. To isolate total 307 
envelope proteins, this total envelope pellet was solubilised using 200 μL of 30 mM Tris-HCl 308 
pH 8 containing 0.5% (w/v) SDS.  309 
LC-MS/MS shotgun proteomic analysis was performed as described previously (32). Analysis 310 
was repeated three times for each parent and mutant strain, each using a separate batch of 311 
cells. Specific protein abundance was normalised based on the average abundance of the 50 312 
most abundant proteins in each sample. Comparisons of normalised abundance between 313 
samples used an unpaired t-test, and significance was defined with p <0.05. Fold-change in 314 
abundance between strains was calculated by first calculating average normalised abundance 315 
across the three samples representing each strain. 316 
 317 
Whole genome sequencing to identify mutations 318 
Whole genome resequencing was performed by MicrobesNG (Birmingham, UK) on a HiSeq 319 
2500 instrument (Illumina, San Diego, CA, USA). Reads were trimmed using Trimmomatic 320 
(39) and assembled into contigs using SPAdes 3.10.1 (http://cab.spbu.ru/software/spades/). 321 
Assembled contigs were mapped to the K. pneumoniae Ecl8 reference genome (GenBank 322 
accession number GCF_000315385.1) (34), obtained from GenBank by using progressive 323 
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Figure Legends 334 
 335 
Figure 1. Arn protein abundance in parent strain Ecl8 versus three mgrB mutants. 336 
Strains were grown in CAMHB and raw envelope protein abundance data for each Arn protein 337 
in a sample are presented normalised using the average abundance of the 50 most abundant 338 
proteins in that sample. Data for three biological replicates of parent (Ecl8) and mgrB mutants 339 
(P21, P22 and P23) are presented as mean +/- Standard Error of the Mean. All mutants have 340 
statistically significantly increased production of all Arn proteins relative to Ecl8 based on a t-341 
test (p<0.05). 342 
 343 
Figure 2. Arn protein abundance in mgrB loss-of-function mutant P23 versus its phoP. 344 
pmrD and pmrA loss-of-function mutant derivatives. 345 
Strains were grown in CAMHB and raw envelope protein abundance data for each Arn protein 346 
in a sample are presented normalised using the average abundance of the 50 most abundant 347 
proteins in that sample. Data for three biological replicates of parent (P23) and mutants where 348 
phoP, pmrD or pmrA had been insertionally inactivated (PhoP-, PmrD- or PmrA-) are 349 
presented as mean +/- Standard Error of the Mean. All PhoP- mutants have statistically 350 
significantly reductions in production of all Arn proteins relative to P23 based on a t-test 351 
(p<0.05). For PmrD- and PmrA- mutants, significant changes relative to P23 are noted with a 352 
star. 353 
 354 
Figure 3. Arn protein abundance in mgrB mutant P23 versus clinical isolate KP47 and 355 
PhoQ* or PmrB* (activatory) mutant derivatives. 356 
Strains were grown in CAMHB and raw envelope protein abundance data for each Arn protein 357 




proteins in that sample. Data for three biological replicates of parent (KP47) and mutants 359 
where PhoQ or PmrA have been activated, compared with the mgrB loss-of-function mutant 360 
P23 are presented as mean +/- Standard Error of the Mean. All Arn proteins, and all Arn 361 
proteins except ArnB are significantly upregulated relative to KP47 in its PhoQ* mutant, and 362 
PmrB* mutant, respectively based on a t-test (p<0.05). For the PmrB* mutant, significantly 363 
lower abundances relative to the PhoQ* mutant are noted with a star. 364 
 365 
Figure 4. PmrA, B, C and E protein abundance in mgrB mutant P23 versus clinical 366 
isolate KP47 and PhoQ* or PmrB* (activatory) mutant derivatives. 367 
Strains were grown in CAMHB and raw envelope protein abundance data for each Pmr protein 368 
in a sample are presented normalised using the average abundance of the 50 most abundant 369 
proteins in that sample. Data for three biological replicates of parent (KP47) and mutants 370 
where PhoQ or PmrA have been activated, compared with the mgrB loss-of-function mutant 371 
P23 are presented as mean +/- Standard Error of the Mean. PmrA, B and C were significantly 372 
upregulated relative to KP47 in its PmrB* mutant based on a t-test (p<0.05). No other 373 




















Values reported are the modes of three repetitions. Shading indicates resistance according to 391 
susceptibility breakpoints set by the CLSI (38). 392 
 393 
Strain/ mutant Colistin MIC (µg.mL-1) 
Ecl8 1 
P21 (mgrB) 64 
P22 (mgrB) 32 
P23 (mgrB) 128 
P23 phoP 2 
P23 pmrD 64 
P23 pmrA 64 
KP47 2 
KP47 PhoQ* 64 




Table 2: Significant changes in envelope protein abundance seen in K. pneumoniae mutant P23 phoP versus P23 394 
Strains were grown in CAMHB and raw abundance data for each protein in a sample are presented normalised using the average abundance of 395 
the 50 most abundant proteins in that sample. Data for three biological replicates of colistin resistant mgrB mutant P23 and its phoP insertionally 396 
inactivated derivative. Proteins listed are those significantly (based on t-test) differently up- (fold change >1) or down-regulated (fold change <1) 397 
in P23 phoP versus P23; considering only proteins that were oppositely regulated in P23 compared with its colistin susceptible parent, Ecl8, as 398 
listed in Table S1. Shading indicates proteins not upregulated in the PhoQ* (activatory) mutant of K. pneumoniae clinical isolate KP47 relative to 399 
KP47; the other 15/18 proteins not shaded are therefore considered the core PhoPQ regulon, see text. Stars indicate proteins encoded by 400 
transcripts upregulated in a K. pneumoniae PhoQ activatory mutant (20). 401 
Accession Description P23 1 P23 2 P23 3 phoP 1 phoP 2 phoP 3 Fold Change t-test 
A6T4W9 GlnD 0.005 0.011 0.009 0.005 0.002 0.003 0.408 0.027 
A6T5U9 Putative periplasmic binding protein 0.036 0.029 0.024 0.000 0.000 0.000 <0.01 0.001 
A6T5Y8 Mg2+ transport ATPase* 0.033 0.041 0.032 0.002 0.000 0.000 0.018 <0.005 
A6T6X6 MacA* 0.016 0.024 0.021 0.006 0.010 0.002 0.305 0.005 
A6T7D1 Hypothetical Protein 0.017 0.021 0.022 0.016 0.014 0.013 0.714 0.019 
A6T7F8 Thymidylate kinase  0.021 0.018 0.016 0.016 0.013 0.011 0.740 0.039 
A6T7J8 PhoP* 0.087 0.105 0.125 0.011 0.000 0.000 0.036 <0.005 
A6T9Y9 SlyB* 1.833 2.191 1.513 0.669 0.634 0.697 0.361 0.002 
A6TBQ4 Lipid A 1-diphosphate synthase 0.122 0.153 0.122 0.012 0.000 0.000 0.030 <0.005 
A6TBT1 ApbE* 0.043 0.045 0.038 0.014 0.005 0.005 0.189 <0.005 
A6TCT2 LpxO* 0.048 0.052 0.037 0.009 0.000 0.003 0.081 0.001 
A6TF96 ArnT* 0.040 0.070 0.035 0.000 0.000 0.000 <0.01 0.006 
A6TF97 ArnD* 0.071 0.041 0.041 0.000 0.000 0.000 <0.01 0.004 
A6TF98 ArnA* 0.496 0.309 0.321 0.000 0.000 0.000 <0.01 <0.005 
A6TF99 ArnC* 0.236 0.313 0.247 0.000 0.000 0.000 <0.01 <0.005 
A6TFA0 ArnB* 0.098 0.051 0.053 0.000 0.000 0.000 <0.01 0.006 
A6THH1 MgtA* 0.025 0.036 0.031 0.000 0.000 0.000 <0.01 <0.005 
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